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ORIGINAL ARTICLE
Synergistic antitumor activity of lenalidomide with the BET
bromodomain inhibitor CPI203 in bortezomib-resistant mantle
cell lymphoma
A Moros1, V Rodrı´guez1, I Saborit-Villarroya1, A Montraveta1, P Balsas1, P Sandy2, A Martı´nez3, A Wiestner4, E Normant2, E Campo1,3,
P Pe´rez-Gala´n1, D Colomer1,3 and G Roue´1
Bortezomib therapy has shown promising clinical activity in mantle cell lymphoma (MCL), but the development of resistance to
proteasome inhibition may limit its efﬁcacy. To unravel the factors involved in the acquisition of bortezomib resistance in vivo,
immunodeﬁcient mice were engrafted with a set of MCL cell lines with different levels of sensitivity to the drug, followed by
gene expression proﬁling of the tumors and functional validation of the identiﬁed gene signatures. We observed an increased
tumorigenicity of bortezomib-resistant MCL cells in vivo, which was associated with plasmacytic differentiation features, like interferon
regulatory factor 4 (IRF4) and Blimp-1 upregulation. Lenalidomide was particularly active in this subgroup of tumors, targeting IRF4
expression and plasmacytic differentiation program, thus overcoming bortezomib resistance. Moreover, repression of the IRF4 target
gene MYC in bortezomib-resistant cells by gene knockdown or treatment with CPI203, a BET (bromodomain and extra terminal)
bromodomain inhibitor, synergistically induced cell death when combined with lenalidomide. In mice, addition of CPI203 to
lenalidomide therapy further decreased tumor burden, involving simultaneous MYC and IRF4 downregulation and apoptosis
induction. Together, these results suggest that exacerbated IRF4/MYC signaling is associated to bortezomib resistance in MCL in vivo
and warrant clinical evaluation of lenalidomide plus BET inhibitor combination in MCL cases refractory to proteasome inhibition.
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INTRODUCTION
Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm
characterized by the translocation t(11;14)(q13;q32) that leads to
aberrant overexpression of cyclin D1 and a number of secondary
chromosomal and molecular alterations affecting the cell cycle,
senescence and cellular response to DNA damage.1 Conventional
chemotherapy induces high remission rates in previously
untreated patients, but relapses within a few years are common,
being the median survival 5–7 years.2
The ﬁrst-in-class proteasome inhibitor bortezomib (VELCADE) is
a potent and reversible inhibitor of the 26S proteasome activity,
approved in 2006 as second-line treatment for MCL.3,4 Bortezomib
induces response rates of 30% to 50% in patients with relapsed
disease, irrespective of their sensitivity to prior therapy.5–7
However, more than half of all MCL patients are intrinsically
resistant or develop resistance to bortezomib.2 The molecular
bases underlying this resistance have not been totally deﬁned in
in vivo settings, although in vitro approaches recently pointed out
an important role of oxidative and endoplasmic reticulum stress,8
closely linked to the activation of the cytoprotective arm of the
unfolded protein response.9 In addition, bortezomib-resistant MCL
cell lines and primary tumor samples both harbor features
characteristic of partial plasmacytic differentiation, including
increased expression and transcriptional activity of interferon
regulatory factor 4 (IRF4) and of the plasma-cell surface markers
CD38 and CD138.10 Although a physiological role of IRF4 in MCL
pathogenesis requires further elucidation, this crucial regulator
of B-cell differentiation and expansion was originally identiﬁed
as an oncogene transcriptionally activated by t(6;14)(p25;q32)
chromosomal translocation in multiple myeloma (MM), where its
expression is associated with a poor prognosis.11,12 MM cells were
further shown to be addicted to an aberrant IRF4 regulatory
network, involving an auto-regulatory control mechanism of IRF4
by its target gene MYC.13
Currently under active investigation for the treatment of B-cell
neoplasms, the immunomodulatory drug lenalidomide has recently
shown to be well tolerated and to produce rapid and durable
responses in heavily pre-treated patients with aggressive, relapsed/
refractory MCL, including patients who had failed bortezomib
therapy.14–17 In addition, a promising overall response rate of
lenalidomide in combination therapy has been observed in MCL
patients with a poor response to initial treatment.18 Of interest, the
direct antitumor activity of lenalidomide has been shown to rely on
the inhibition of the IRF4/MYC loop, and to depend on the level of
expression of the E3 ligase protein cereblon (CRBN) in both MM
cells and in the activated B-cell-like subtype of diffuse large B-cell
lymphoma (ABC-DLBCL).19–22
Our aim was to validate IRF4 overexpression and plasmacytic
differentiation as markers of bortezomib resistance in in vivo
xenotransplantation models of MCL, and to assess the possibility
of targeting IRF4/MYC signaling and overcoming bortezomib
resistance using lenalidomide-based therapies.
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MATERIALS AND METHODS
Cell lines and primary samples
The nine human MCL cell lines (Z-138, ZBR, JeKo-1, JBR, REC-1, JVM-2,
GRANTA-519, UPN-1 and Mino) used in this study were cultured, routinely
tested for Mycoplasma infection and checked for their identity as
previously described.9 Primary MCL cells from four previously untreated
patients (see clinical characteristics in Supplementary Table 1), diagnosed
according to the World Health Organization (WHO) classiﬁcation criteria23
were used. The ethical approvals for this project including the informed
consent of the patients were granted following the guidelines of the
Hospital Clı´nic Ethics Committee (Institutional Review Board). Mononuclear
cells were isolated from peripheral blood by Ficoll/Hypaque sedimentation
(GE Healthcare, Chalfont St Giles, UK) and stored in the Hematopathology
Biobank of our institution (Biobanks from CDB-IDIBAPS-Hospital Clı´nic).
Xenograft mouse model and tumor phenotyping
CB17-severe combined immunodeﬁciency (SCID) mice (Charles River
Laboratories, L’Arbresle, France) were inoculated subcutaneously with
107 cells of the indicated MCL cell line, and monitored for tumor growth
and vital parameters as previously described.9 For lenalidomide (kindly
provided by Celgene Corporation, Summit, NJ, USA) and lenalidomide–
bortezomib dosing, mice were randomly assigned into cohorts of 3–4 mice
each and received by intraperitoneal injection a twice weekly dose of
bortezomib (0.15mg/kg, kindly provided by Millenium/Takeda Oncology,
Cambridge, MA, USA), a daily dose of lenalidomide (50mg/kg), the
combination of lenalidomide and bortezomib, or an equal volume of
vehicle. In the lenalidomide–CPI203 protocol (CPI203 was kindly provided
by Constellation Pharmaceuticals, Cambridge, MA, USA), a total of 22 REC-1
tumor-bearing mice were randomly assigned to cohorts of 5–6 mice,
receiving a twice daily intraperitoneal injection of 2.5mg/kg CPI203, a daily
intraperitoneal injection of 50mg/kg lenalidomide, both agents or an
equal volume of vehicle. Between 26 and 29 days post-inoculation, animals
were killed according to institutional guidelines and tumor samples were
subjected to immunohistochemical staining using primary antibodies
against phospho-histone H3 (Epitomics, Burlingame, CA, USA), cleaved
caspase-3 (5A1E) and MYC (D84C12) (Cell Signaling Technology, Beverly,
MA, USA), IRF4 (M-17) and platelet endothelial cell adhesion molecule-1
(PECAM-1) (M20) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD19
(LE-CD19) (Dako, Glostrup, Denmark), Blimp-1 (clone Ros195G/G5, kindly
provided by G Roncador, Spanish National Cancer Centre, Madrid, Spain),
PAX5 (clone 24, Becton Dickinson, San Jose, CA, USA), CCL3 (R&D Systems,
Minneapolis, MN, USA) and CD38 (Sigma-Aldrich, St Louis, MO, USA), as
previously described.9 Preparations were evaluated using an Olympus
DP70 microscope and Cell B Basic Imaging Software (Olympus, Hamburg,
Germany).
Gene expression proﬁling
Total RNA was extracted from representative tumors derived from JeKo-1
(n¼ 5) and JBR (n¼ 2) cell lines using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). Complementary RNA was hybridized on the HT HG-U219
GeneChip (Affymetrix, Santa Clara, CA, USA) following standardized
protocols. Scanning was processed in a Gene Titan instrument and
analyzed with GeneChip Command Console Software (Affymetrix). Raw
data were normalized using the Robust Multichip Analysis algorithm
implemented in the Expression Console Software v1.1 (Affymetrix). An
enrichment pathway analysis was done using the gene set enrichment
analysis desktop application version 2.0 (http://www.broadinstitute.org/
gsea/) in order to ﬁnd signiﬁcant gene signatures using experimentally
derived custom gene sets (http://lymphochip.nih.gov/signaturedb/
index.html).24 A two-class analysis with 1000 permutations of gene sets
and a weighted metric was used. Gene sets with a false discovery rate
below 0.05 were considered to be signiﬁcant. The leading edge of enriched
gene sets, the subset of genes that contributed the most to the
enrichment result, were displayed using the Cluster v2.11 and TreeView
v1.6 programs (Eisen Laboratory University of California at Berkeley, CA,
USA). Primary microarray data are available at the Gene Expression
Omnibus of the National Center for Biotechnology Information (GSE51371).
Cytoﬂuorimetric analysis
Phosphatidylserine exposure was quantiﬁed by staining with annexin V as
described.25 CD38 expression was determined by staining cells with a
phycoerythrin-labeled anti-CD38 antibody, using an immunoglobulin G1
isotype-phycoerythrin as negative control (Becton Dickinson). Ten thousand
stained cells per sample were acquired and analyzed in an Attune acoustic
focusing cytometer using Attune software (Life Technologies, Carlsbad,
CA, USA).
Western blot assays
Five millions cells were lysed in Triton buffer as previously described9 and
50mg proteins were transferred onto polyvinylidene diﬂuoride membranes
(Immobilon-P, Millipore, Billerica, MA, USA) and probed with antibodies
against MYC or IRF4 and the endogenous b-actin (Sigma-Aldrich), followed
by incubation with anti-rabbit (Cell Signaling Technology), anti-goat (Santa
Cruz Biotechnology) or anti-mouse (Sigma-Aldrich) secondary antibodies.
Chemiluminiscence detection was done by using ECL system (Thermo
Fisher, Waltham, MA, USA) in a mini-LAS4000 device with Image Gauge
software (Fujiﬁlm, Tokyo, Japan).
RNA isolation and real-time PCR
Total RNA was extracted using TRIZOL (Life Technologies) following the
manufacturer’s instructions. One microgram of RNA was retrotranscribed
to complementary DNA using moloney murine leukemia virus reverse
transcriptase (Life Technologies) and random hexamer primers (Roche,
Basel, Switzerland). mRNA expression was analyzed in duplicate by
quantitative real-time PCR on the Step one system by using predesigned
Assay-on-Demand primers and probes (Life Technologies). The relative
expression of each gene was quantiﬁed by the comparative cycle
threshold method (DDCt). b-Actin was used as an endogenous control.
RNA interference assay
REC-1 cells (7 106) were electroporated with a Nucleofector Device
(Lonza, Verviers, Belgium, program A-032) Ingenio Electroporation Solution
(Mirus, Madison, WI, USA) containing either 2.5mM of a Silencer Select
Predesigned small interfering RNA (siRNA) targeting the MYC gene, a mix
of two Silencer Select Predesigned siRNA targeting the IRF4 gene or a non-
silencing (scramble) siRNA (Ambion, Austin, TX, USA), or 200 nM of a mix of
three different predesigned siRNA-targeting CRBN gene or a control duplex
siRNA (Integrated DNA Technologies, Leuven, Belgium). After transfection,
cells were transferred to culture plates for 6h before experiments were set up.
Cell proliferation assay
MCL primary cells (1.5 105) and cell lines (4 104) were incubated as
indicated with lenalidomide and/or CPI203. MTT (3-(4,5-dimethylthiazolyl-
2)-2,5-diphenyltetrazolium bromide) reagent (Sigma-Aldrich) was added
for 2–6 additional hours before spectrophotometric measurement. Each
measurement was made in triplicate. Values were represented using
untreated control cells as reference. The GI50 was calculated as the
concentration that produced 50% growth inhibition. Combination indexes
(CIs) were calculated by using the Calcusyn software version 2.0 (Biosoft,
Ferguson, MO, USA). The interaction between two drugs was considered
synergistic when CIo1.
Statistical analysis
Data are represented as mean (± s.d. or s.e.m) of three independent
experiments. All statistical analyses were done using GraphPad Prism 4.0
software (GraphPad Software, Inc., La Jolla, CA, USA). Comparisons
between two groups of samples were evaluated by the Student’s t-test
or nonparametric Mann–Whitney test. Results were considered statistically
signiﬁcant when Po0.05.
RESULTS
Bortezomib resistance correlates with plasmacytic differentiation
and increased tumorigenecity in vivo
To investigate the impact of bortezomib resistance on MCL cell
tumorigenicity, three MCL cell lines with acquired or constitutive
resistance to bortezomib (JBR, ZBR and REC-1), as well as four
bortezomib-sensitive cell lines (JeKo-1, Z-138, JVM-2 and GRANTA-
519) were inoculated in immunodeﬁcient mice to generate the
corresponding MCL xenograft models. The generation and
characterization of JBR and ZBR, derived from the parental,
bortezomib-sensitive cell lines JeKo-1 and Z-138, respectively,
have been described previously.9 Although these cell lines did not
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show noticeable differences in their growth properties in vitro
(data not shown), a signiﬁcant increase in tumor burden was
observed 4 weeks after the inoculation in animals engrafted with
the bortezomib-resistant cell lines compared with the mice
bearing bortezomib-sensitive tumors (Figure 1a). To investigate
the molecular basis of this phenomenon, we compared the gene
expression proﬁling of tumors derived from the representative
bortezomib-sensitive cell line JeKo-1 and its derived bortezomib-
resistant subclone JBR. A ﬁrst inspection of gene expression
proﬁling results indicated the upregulation of genes related to
Figure 1. Increased tumorigenecity of bortezomib-resistant cell lines is associated with plasmacytic differentiation. (a) A set of bortezomib-
resistant (black curves) and bortezomib-sensitive (gray curves) MCL cell lines were subcutaneously inoculated into 3–9 SCID mice and tumor
growth was recorded for up to 27 days. (b) Gene expression signatures of plasma-cell differentiation distinguish tumors derived from the
representative, bortezomib-resistant cell line JBR, from tumors derived from the parental, bortezomib-sensitive cell line JeKo-1. The leading
edge of each gene set is displayed in a heat map. NES, normalized enrichment score. (c) Changes in the expression of selected plasma-cell
markers were confirmed by immunohistochemical staining of consecutive sections from tumors representative of each subgroup.
Bortezomib-resistant tumors harbored several hallmarks of plasmacytic differentiation including increased IRF4 and Blimp-1 levels and
decreased of PAX5 expression, accompanied by an increase in mitotic index revealed by p-histone H3 staining and by the apparition of
CCL3-secreting cells (white arrows) (magnification  800).
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plasma-cell differentiation and the downregulation of B-cell genes
in JBR-derived tumors. To determine the signiﬁcance of these
changes, we performed gene set enrichment analysis with well-
deﬁned gene signatures of plasma-cell differentiation, as pre-
viously described.10 All of these signatures were signiﬁcantly
enriched in the tumors derived from JBR cells, indicating a shift
from a B-cell to a plasmacytic gene expression program
(Figure 1b). Immunohistological analysis conﬁrmed that an
increased mitotic index, as assessed by phospho-histone H3
labeling, was associated with marked upregulation of the
Figure 2. Antitumoral activity of lenalidomide is mediated by inhibition of the plasmacytic differentiation program in bortezomib-resistant
MCL. (a) A set of nine MCL cell lines were incubated for 72 h with 1 mM lenalidomide and cytotoxicity was assessed by MTT assay. The relative
number of proliferating cells compared with untreated cells is presented as the mean (s.d.) of triplicate assays. (b) IRF4 protein downregulation
after lenalidomide treatment (1mM, 72 h) was analyzed by western blot in six representative bortezomib-resistant and bortezomib-sensitive
MCL cell lines. Cell viability was assessed by cytofluorimetric detection of Annexin V-positive cells. (c) REC-1 cells treated as in b were
analyzed by flow cytometry for their membrane levels of CD38; r values refer to the mean fluorescence ratio between the mean fluorescence
intensity of the CD38-phycoerythrin (PE) signal in treated sample and untreated sample and an isotypic control, using untreated cells as a
calibrator. (d) REC-1 cells were electroporated in the presence of CRBN or negative control siRNA and CRBN and IRF4 protein levels were
evaluated by western blot. b-Actin was used as a loading control (upper panel). Transfected cells were either untreated or treated with 5 mM
lenalidomide for 72 h and cell proliferation was evaluated by MTT assay (lower panel). (e) REC-1 cells (107 cells per mouse) were
subcutaneously inoculated into the right flank of SCID mice. Tumor-bearing mice (n¼ 3–4 mice per group) received intraperitoneal injections
of 50mg/kg lenalidomide or an equal volume of vehicle, 5 days a week, for 3 weeks. Tumor volumes were measured at the end of the
treatment period with external calipers. (f ) Representative tumor samples were then assessed by immunohistochemical staining for mitotic
index (p-histone H3), angiogenesis (platelet endothelial cell adhesion molecule-1 (PECAM-1)), plasmacytic differentiation (IRF4, CD38, Blimp-1
and CCL3) and B-cell related markers (PAX-5). White arrows: CCL3-producing cells (magnification  800).
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plasmacytic markers IRF4, Blimp-1 and CD38, together with a loss
of the common B-cell markers PAX5 and CD19, in JBR versus JeKo-1
tumors (Figure 1c and Supplementary Figure S1A). IRF4 staining,
scored by an expert pathologist in three degrees referring to the
level of expression observed in plasma cells, revealed that in JeKo-1
tumors, 5% and 60% of the cells were scored as 3þ /3 and
1þ /3þ , respectively, contrasting with JBR tumors where 50% of
the cells were scored as 3þ /3 and 40% of the cells as 2þ /3þ
(Figure 1c). In accordance with previously published data,10 IRF4
was found to be a crucial regulator of MCL sensitivity to
bortezomib as its siRNA-mediated downregulation signiﬁcantly
increased REC-1 cell response to the proteasome inhibitor
(Supplementary Figure S2A). Further, as part of the IRF4 gene
signature, JBR, but not JeKo-1 tumors exhibited an eightfold
increase in CCL3mRNA and CCL3 protein expression together with
a sevenfold increase in IRF4 mRNA (Figure 1c, Supplementary
Figures S1A, S2B and S2C). In agreement with a physiological role
of this chemokine in the regulation of IRF4/MYC signaling and
MCL resistance to bortezomib, treatment of JeKo-1 cells with
recombinant CCL3 was shown to increase MYC expression and to
limit the pro-apoptotic activity of bortezomib in these cells
(Supplementary Figures S2D and S2E). Together, these results
suggest that the acquisition of a plasmacytic phenotype by
bortezomib-resistant MCL cells may confer increased tumorigenicity
in vivo.
Lenalidomide counteracts IRF4 upregulation and plasmacytic
differentiation program in bortezomib-resistant cell lines and
tumors
As lenalidomide activity has been shown recently to rely on IRF4
downregulation in MM and ABC-DLBCL,19,21 we assessed whether
the drug could exert such activity in MCL cells resistant to
bortezomib. Figure 2a and Table 1 show an inverse correlation
between the response to lenalidomide and the degree of
sensitivity to bortezomib in a panel of nine MCL cell lines. Indeed,
lenalidomide was found to be signiﬁcantly (P¼ 0.01) more active
in bortezomib-resistant cells where it exerted an average
cytostatic effect of 33.6%, when compared with the bortezomib-
sensitive subset of cell lines (mean effect: 4.8%). This phenomenon
was associated with a remarkable inhibition of IRF4 overexpres-
sion in bortezomib-resistant cells exposed to lenalidomide, while
the lower, basal IRF4 levels observed in the bortezomib-sensitive
cells were almost unmodiﬁed by the treatment (Figure 2b).
Accordingly, the cytoﬂuorimetric quantiﬁcation of CD38 revealed
a 55% decrease in the expression of this marker in REC-1 cells
exposed to lenalidomide, when compared with untreated cells
(Figure 2c). To explore the requirement of CRBN for lenalidomide-
mediated cytotoxicity and IRF4 downregulation, we selectively
knocked down the CRBN gene in REC-1 cells by a siRNA approach
prior lenalidomide treatment. When compared with cells trans-
fected with a non-targeting siRNA, the combination of three
different oligonucleotides against CRBN effectively blocked the
synthesis of the protein, leading to IRF4 downregulation and a
decrease in the antitumor activity of lenalidomide from 37 to
23.9% (P¼ 0.01; Figure 2d). Accordingly, in the absence of CRBN,
lenalidomide-mediated decrease in IRF4 protein levels was
partially impaired after a 72-h exposure to the drug
(Supplementary Figure S3). Of note, IRF4 downregulation in CRBN
knockdown cells was also associated with a slight increase
(þ 19.5%) in the rate of apoptotic cells, underlying the
dependence of REC-1 toward this factor for their survival
(Figure 2d). Thus, as previously described in MM and ABC-DLBCL
cell lines, the in vitro activity of lenalidomide in bortezomib-
resistant MCL cell lines may involve the downregulation of IRF4 in
a CRBN-dependent manner.
To validate these results in vivo, CB17-SCID mice bearing REC-1
cell-derived tumors were randomly assigned to treatment with
lenalidomide (50mg/kg, daily) or vehicle. As shown on ﬁgure 2e,
after 3 weeks of treatment, tumors from lenalidomide-treated
mice had a signiﬁcant (P¼ 0.04) lower volume than tumors from
the vehicle group. The immunohistochemistry analysis of repre-
sentative tumor sections revealed that lenalidomide therapy
efﬁciently reduced the hallmarks of bortezomib resistance and
aggressiveness in REC-1 tumors, such as phospho-histone H3,
IRF4, CD38, Blimp-1 and CCL3, and restored the expression of
PAX5 (Figure 2f and Supplementary Figure S1B). Western blot
analysis of representative whole tumor specimens, indicated that
IRF4 and its target gene MYC experimented a 35% and a
85% protein decrease after lenalidomide therapy, respectively
(Supplementary Figure S1E). In addition, the interferon-regulated
genes CXCL10 and CXCL11 were the most downregulated genes in
lenalidomide-receiving tumors among a panel of 90 genes related
to immune regulation (data not shown), in agreement with
previous ﬁndings in ABC-DLBCL cells.20 Finally, lenalidomide was
also able to reduce the length and number of intramural tumor
blood vessels, as shown by a reduction in platelet endothelial cell
adhesion molecule-1 staining (Figure 2f and Supplementary
Figure S1B). Thus, lenalidomide activity appeared to be stronger
in MCL cell lines and tumors resistant to bortezomib, mediated by
the downregulation of IRF4 and plasma-cell-related antigens and
cytokines, and impaired angiogenesis.
Lenalidomide is able to overcome bortezomib resistance in vivo
In an attempt to assess whether lenalidomide could reverse MCL
resistance to bortezomib in vivo, mice inoculated with REC-1 cells
as above were assigned to four different treatment arms:
bortezomib 0.15mg/kg twice per week, lenalidomide 50mg/kg
daily, a combination of both agents or equal volume of vehicle.
Although administration of bortezomib as a single agent did not
affect tumor burden, mice receiving lenalidomide showed a 45%
reduction in tumor growth when compared with vehicle group
(Figure 3a). This effect was greatly enhanced by the addition of
bortezomib to lenalidomide, reaching a 37% and 67% tumor
decrease when compared with lenalidomide and vehicle arms,
respectively, in the absence of drug-related toxicity. Accordingly,
although tumor metabolism was almost unaffected by bortezomib
treatment, lenalidomide and lenalidomide plus bortezomib
therapies led to a 43% and a 94% reduction in glucose uptake,
respectively, indicative of synergy between these two compounds
in vivo (Figure 3b). The histological analysis of the corresponding
tumors conﬁrmed a stronger reduction of tumor mitotic index by
the combination therapy, together with a profound downregulation
of IRF4 (Figure 3c and Supplementary Figure S1C). Importantly,
although some degree of apoptosis could be detected by means of
activated-caspase-3 staining in the lenalidomide, but not in the
control or bortezomib arms, the tumors from combination-
receiving mice showed a remarkable accumulation of apoptotic








JVM-2 Sensitive o1 0.21±0.02
Z-138 Sensitive 8.5 0.14±0.01
Granta-519 Sensitive o1 0.71±0.03
JeKo-1 Sensitive o1 0.26±0.05
UPN-1 Sensitive 12.6 0.08±0.002
REC-1 Resistant 45.7 0.21±0.03
Mino Resistant 16.4 0.06±0.03
JBR Resistant 44.1 0.18±0.05
ZBR Resistant 28.1 0.19±0.06
Abbreviation: MCL, mantle cell lymphoma.
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cells (Figure 3c and Supplementary Figure S1C). Taking together,
these results suggest that the bortezomib–lenalidomide combina-
tion is able to overcome bortezomib resistance of MCL tumors
in vivo, via the inhibition of IRF4 expression, impaired cellular
proliferation and induction of apoptosis.
A role for MYC in the response of bortezomib-resistant cells to
lenalidomide
According to the above results, bortezomib-resistant MCL may
present several similarities with myeloma cells in terms of IRF4
expression and response to lenalidomide. As MYC has been
described as a direct target gene of IRF4 in this latest model,13 we
further assessed the levels of this oncogene in bortezomib-resistant
MCL tumors and its role in lenalidomide-treated cells. Figures 4a and b
show that MYC was upregulated in JBR versus JeKo-1 tumors, in
agreement with the difference in mitotic index previously observed
between the two sets of tumors. Accordingly, a two- to threefold
increase in MYC mRNA levels was detected by quantitative reverse
transcriptase-PCR in JBR and REC-1-derived tumors when compared
with JeKo-1-derived specimen, indicative of a transcriptional
upregulation of the gene (Supplementary Figure S4). To further
Figure 3. Lenalidomide overcomes bortezomib resistance in vivo. (a) Mice were inoculated with REC-1 cells as previously described and began
treatment at day 9 post-inoculation with 50mg/kg lenalidomide, 0.15mg/kg bortezomib, both agents or equal volume of vehicle.
Lenalidomide was administrated 5 days a week and bortezomib twice a week, for up to 18 days. (b) Left panel, intratumoral glucose uptake
was evaluated in representative mice injected intravenously with an IR800-labeled 2-deoxy glucose probe 24 h prior killing, and visualized
with an Odyssey infra-red scanner (Li-Cor, Lincoln, NE, USA). Right panel, relative fluorescence quantification by means of the Image Studio
software (Li-Cor) shows markedly reduced glucose uptake in tumor masses from mice receiving lenalidomide or the lenalidomide–bortezomib
combination, when compared with either vehicle- or bortezomib-treated animals. (c) Immunohistochemical staining of consecutive sections
from representative tumors, pointing out the synergistic downregulation of IRF4 and proliferation, and induction of apoptosis by the
lenalidomide and bortezomib combination in REC-1-derived tumors (magnification  200).
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characterize the role of MYC in the response of bortezomib-resistant
MCL cells to lenalidomide, we used a siRNA approach to selectively
downregulate MYC protein synthesis in REC-1 cells, followed by a
48-h treatment with lenalidomide. The speciﬁc MYC-targeting
oligonucleotide used was able to abrogate MYC expression in
REC-1 cells, compared with cells transfected with a non-targeting
siRNA (Figure 4c). MYC knockdown was then shown to induce a
20% reduction in REC-1 cell proliferation. When combined with
lenalidomide, we observed a complementary downregulation of
MYC and an enhanced antiproliferative effect that reached 50%
(Figures 4c and d). Thus, in addition to IRF4 expression, MYC
upregulation appears to be a hallmark of MCL resistance to
bortezomib, and may condition MCL response to lenalidomide.
The BET bromodomain inhibitor CPI203 exerts cytostatic effect
and synergistically increased lenalidomide-induced apoptosis in
MCL cells
Based on the recent demonstration that pharmacologic inhibition
of MYC is achievable through targeting bromodomain and extra
terminal (BET) family of chromatin adapters,26,27 we assessed the
possible role of MYC in the response of MCL to lenalidomide by
evaluating the anti-proliferative activity of CPI203, a potent,
selective and competitive small molecule inhibitor of BET
proteins.28,29 As shown in Figure 5a and Table 1, CPI203 exerted
a cytostatic effect in the nanomolar range in all the nine MCL cell
lines analyzed, independently of their sensitivity to either
bortezomib or lenalidomide, with a mean GI50 value at 72 h of
0.23mM (range: 0.06–0.71 mM). At this concentration, the cytotoxi-
city of the compound in normal peripheral blood mononuclear
cells from healthy donors was below 25%, thus demonstrating its
selectivity. Treatment with 0.5 mM CPI203 in two representative
bortezomib-resistant MCL cell lines with high MYC basal levels
(REC-1, JBR) and two representative bortezomib-sensitive MCL cell
lines harboring lower expression of the oncogene (GRANTA-519
and JVM-2), effectively reduced MYC expression in all the samples
without inducing apoptosis (Figure 5b). This effect was mediated
by the repression of MYC gene transcription, as conﬁrmed by
quantitative reverse transcriptase-PCR (data not shown). We then
assessed whether CPI203 treatment could enhance MCL response
to lenalidomide. The four bortezomib-resistant MCL cell lines
REC-1, MINO, JBR and ZBR, together with four lenalidomide-
sensitive primary cultures, were treated with a 0.1 or 0.5 mM dose
of CPI203, followed by a 72-h exposure to 1 or 5 mM lenalidomide,
and the CI values were calculated. At both 0.1 and 0.5 mM doses,
CPI203 exerted a synergistic cytotoxic effect with lenalidomide
5 mM on all the samples analyzed. For lenalidomide–CPI203 0.1 mM
combination, the median CI was 0.35 (range: 0.19–0.57) in the cell
lines and 0.39 (range: 0.07–0.56) in the primary cultures. For
lenalidomide–CPI203 0.5 mM combination, the median CI was 0.5
(range: 0.29–0.55) in the cell lines and 0.52 (range: 0.05–0.64) in
the primary cultures. Figure 5c shows representative data
obtained from REC-1 cells and primary cells from MCL patient #4.
Consistently, while lenalidomide alone could partially reduce
MYC expression, together with IRF4, in REC-1 cells, the combina-
tion of both agents almost completely abrogated the expression
of both factors (Figure 5d). Of note, CPI203 single-agent treatment
also appeared to slightly affect IRF4 expression (Figure 5d),
underlying a possible retro-control of IRF4 expression by MYC in
bortezomib-resistant MCL cells, as previously reported in myeloma
cells.30 Importantly, lenalidomide or CPI203 alone activated the
apoptotic program in these cells only marginally (see Figures 2b
and 5b), whereas the combination of both drugs achieved an
apoptotic response in 470% of the cells (Figure 5d), suggesting
that simultaneous targeting of IRF4 and MYC by lenalidomide and
BET inhibition efﬁciently activates the cell death program in MCL
cells resistant to bortezomib.
The CPI203–lenalidomide combination synergistically inhibits the
growth of bortezomib-resistant tumors in vivo
To further characterize in vivo the synergistic role of lenalidomide
and CPI203, SCID mice inoculated with REC-1 cells were randomly
assigned into drug-treated (lenalidomide 50mg/kg daily, CPI203
2.5mg/kg BID, combo) and vehicle-treated groups. As shown in
Figure 6a, while lenalidomide alone achieved a 41% reduction in
tumor volume when compared with vehicle group, this effect
reached 44% and 62% in mice receiving CPI203 and the
lenalidomide–CPI203 combination, respectively. Similar results
were obtained using a JBR-induced xenotransplant model of
MCL (data not shown). Accordingly, tumor glucose uptake was
reduced to 40–45% in animals treated with either lenalidomide or
CPI203, while this reduction reached 86% in the combo group
(Figure 6b). Immunohistochemical analysis of the corresponding
tumors conﬁrmed a synergistic decrease in the mitotic index,
together with the almost complete disappearance of both
MYC- and IRF4-positive cells, and an accumulation of cleaved
caspase-3-positive cells in the combo-receiving group (Figure 6c
and Supplementary Figure S1D). These results conﬁrmed our
in vitro data, showing that the combination of lenalidomide with
the BET inhibitor CPI203 synergistically augments the antitumoral
properties of each single agent, thanks to the abrogation of MYC
and IRF4 expression and the induction of apoptosis.
Altogether, our results suggest that exacerbated IRF4/MYC
signaling is a hallmark of bortezomib resistance in in vivo models
of MCL and that dual inhibition of IRF4 and MYC by means of
lenalidomide and BET bromodomain inhibitor is a promising
strategy that may warrant clinical activity in MCL cases refractory
to proteasome inhibition.
DISCUSSION
The mechanism of action of bortezomib in MCL is complex, as it
affects many cellular processes as diverse as BCL-2 protein
Figure 4. Role of MYC expression in MCL cell sensitivity to
bortezomib and lenalidomide. (a) Immunohistochemical detection
of increased MYC nuclear levels in bortezomib-resistant vs
bortezomib-sensitive tumors (magnification  800). (b) Western
blot analysis of JBR and JeKo-1 tumor samples (two samples per
group) confirming the accumulation of MYC, in addition to IRF4, in
bortezomib-resistant MCL tumors. (c) MYC siRNA and scrambled
non-silencing siRNA were transferred to REC-1 cells by electropora-
tion and MYC protein levels were evaluated by western blot. b-Actin
was used as a loading control. (d) Transfected cells were either
untreated or treated for 48 h with 1 mM lenalidomide, after which
time cell proliferation was evaluated by MTT assay.
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modulation, reactive oxygen species production, endoplasmic
reticulum stress and unfolded protein response signaling.4 This
diversity of effects may explain, at least in part, the gap between
the promising activity of the drug reported in the ﬁrst preclinical
studies and its clinical efﬁcacy. This also illustrates the need for
in vivo models of bortezomib resistance to validate the markers
and combinational therapies identiﬁed by in vitro approaches.
Here, by analyzing the in vivo properties of a panel of seven
MCL cell lines, including previously described cell lines with
spontaneous or acquired resistance to the proteasome inhibitor,9
we describe for the ﬁrst time that drug-resistant MCL cell lines
have increased tumorigenic properties in vivo, and that the
increased aggressiveness of these tumors correlates with the
expression of a plasmacytic differentiation program, being IRF4
a major regulator of this phenomenon.31,32 This observation
not only conﬁrms the recent identiﬁcation of plasma-cell
differentiation as a surrogate of bortezomib resistance in MCL,10
but it also links for the ﬁrst time this phenotype with increased
tumor angiogenesis, mitotic indexes and MYC expression levels.
Indeed, although MYC is not included in the different gene sets
identiﬁed either by our in vivo gene set enrichment analysis or by
the previous in vitro study,10 we detected a threefold increase in
MYC mRNA levels and a remarkable nuclear accumulation of the
protein in JBR tumors. The evidence presented here suggests that
the major mechanism of MYC upregulation in bortezomib-resistant
tumors is the overexpression IRF4, as the downregulation of
the oncogene is systematically observed after speciﬁc IRF4
knockdown in vitro (data not shown) and following the
Figure 5. CPI203 synergistically induces apoptosis with lenalidomide in bortezomib-resistant cells. (a) A set of nine MCL cell lines and two
peripheral blood mononuclear cell (PBMC) cultures from healthy donors were incubated for 72 h with increasing concentrations of CPI203 and
cytotoxicity was assessed by MTT assay. The relative number of proliferating cells compared with control (untreated cells) are presented as the
mean (s.d.) of triplicate assays. (b) Decreases in MYC protein levels after CPI203 (500 nM, 24 h) treatment was analyzed by western blot in four
MCL cell lines. Cell viability was assessed by cytofluorimetric detection of Annexin V-positive cells. (c) Synergistic effect of lenalidomide and
CPI203 combination in MCL cell lines and primary samples. Cells were treated for 72 h with 0.1–0.5 mM CPI203 and/or 1–5 mM lenalidomide.
Cytotoxicity was determined by the MTT assay, and the CI values were calculated. Shown are the cytotoxicity and the CI values calculated after
treating REC-1 cell with 0.1 mM CPI203 and 5 mM lenalidomide and primary cells from MCL case #4 with 0.5 mM CPI203 and 5 mM lenalidomide.
(d) REC-1 cells were treated as above with 0.5 mM CPI203 and 1–5 mM lenalidomide. MYC and IRF4 levels were determined by western blot, and
cell viability was determined by flow cytometry detection of annexin V binding.
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administration of lenalidomide in vivo. Beside the downregulation
of MYC, this activity of lenalidomide toward IRF4 expression may
allow MCL tumors to partially reverse the plasmacytic
differentiation and to recover their sensitivity to bortezomib
cytotoxic effect. Although such a decrease in IRF4 levels has been
shown to be sufﬁcient to induce apoptosis in MM and ABC-DLBCL
cell lines exposed to similar doses of the immunomodulatory
drug,13,19,20 our present results show that lenalidomide alone
exerts mostly cytostatic effects in MCL cultures. In turn, we found
that dual extinction of both IRF4 and MYC is required to achieve
apoptotic processing in vitro and in vivo, and that both factors may
represent important targets for the therapy of MCL patients, as
described for MM patients.33 Arguing in favor of this notion, IRF4
has been shown to be required for the survival of bortezomib-
resistant MCL cells,10 and overactivation of IRF4/MYC axis has been
proposed as the ‘Achilles’ heel’ of MM and ABC-DLBCL cells.13,20
Figure 6. CPI203 plus lenalidomide synergistically inhibits the growth of bortezomib-resistant tumors. (a) Twenty-four SCID mice were
inoculated with 107 REC-1 cells as previously described. Tumor-bearing mice were randomly assigned to one of the following treatment arms
(n¼ 5–6 mice per group): lenalidomide 50mg/kg daily, CP203 2.5mg/kg BID, both agents or equal volume of vehicle, for 16 days. Tumor
volumes were recorded each 3–4 days as previously. (b) Odyssey software pictures and corresponding fluorescence quantifications from
representative mice at the day of killing. (c) Immunohistochemical labeling of p-histone H3, activated caspase-3, MYC and IRF4 in consecutive
tissue sections from four representative tumor specimens (magnification  200), illustrating the synergistic downregulation of IRF4, MYC and
proliferation, and induction of apoptosis in tumors from mice receiving lenalidomide–CPI203 combination.
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MYC overexpression is associated with shorter survival in MCL
patients, especially in those rare double-hit cases with a MYC-
activating translocation and pleomorphic blastoid morphology.34
First attempts of speciﬁc pharmacological inhibition of MYC
activity were focused on the inhibition of its interaction with its
co-factor MAX complexes by a small molecule approach that,
despite a remarkable efﬁciency in vitro, could not maintain a
signiﬁcant inhibitory activity in in vivo models of Burkitt
lymphoma with t(8;14)(q24;q32) activating translocation.35 More
recently, the use of (þ )-JQ1, a highly potent, selective and cell
permeable inhibitor of BRD4, a member of the BET family of
chromatin adaptors, has shown antitumor activity in MM
xenograft models, mediated by transcriptional inhibition of
MYC.26,36 BET proteins are transcriptional regulators that
selectively recognize and bind to acetylated lysine residues in
histones, and have an important role in cellular maintenance,
proliferation, differentiation and activation. Their deregulation
may result in various cancers, inﬂammatory diseases, metabolic
diseases and tissue degeneration, involving the abnormal
stimulation of transcriptional elongation of certain target genes
including MYC and BCL2 oncogenes.36 Further studies with
(þ )-JQ1 validated BET bromodomain targeting as a promising
therapeutic strategy in BL,27 glioblastoma,37 erythroleukemia,38
high-risk acute lymphoblastic leukemia39 and in aggressive B-cell
lymphoma.40 CPI203 is a BET inhibitor that has shown superior
bioavailability with oral or intraperitoneal administration.28,29 We
found MCL cells to be highly sensitive to CPI203 monotherapy,
including bortezomib-resistant cell lines with increased MYC
basal expression, where the compound achieved remarkable
downregulation of the oncoprotein. We then demonstrated by
both in vitro and in vivo approaches a meaningful synergistic
effect of the CPI203–lenalidomide combination in MCL cases with
intrinsic resistance to bortezomib, because of the capacity of
CPI203 to facilitate lenalidomide-mediated downregulation of IRF4
and MYC.
Although the combination of lenalidomide with bortezomib is a
rational one, given the clinical activity of both drugs in MCL, the
combination of lenalidomide with such a BET protein bromo-
domain inhibitor is less obvious but may offer a glimpse into the
potential opportunities that lenalidomide-based combinations
hold for the treatment of patients with MCL refractory to
bortezomib.
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